News
Zacks Investment Research on MSN3d
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study GoalVertex Pharmaceuticals VRTX reported adjusted earnings of $4.52 per share for the second quarter of 2025, surpassing the ...
Vertex Pharmaceuticals' leading cystic fibrosis franchise still looks promising. It also has a couple of exciting newer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback